title: New developments in juvenile systemic and localized scleroderma.
abstract: Juvenile localized scleroderma (jLS) and juvenile systemic sclerosis (jSS) are both orphan diseases, with jLS around 10 times more frequent than jSS. In recent years the time gap between the appearance of symptoms and diagnosis has become significantly shorter. This review focuses on the new classifications of jSS and jLS, and on the developments and adaptations of the outcome measures for certain organ involvements whereby progress has been made regarding pediatric patients.
authors.affiliation: Hamburger Zentrum für Kinder- und Jugendrheumatologie, Dehnhaide 120, Hamburg 22081, Germany. Electronic address: Sprechstunde@kinderrheumatologie.de.
authors.forename: Ivan
authors.initials: I
authors.lastname: Foeldvari
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D002648:Child; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D020678:Microscopic Angioscopy; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D012594:Scleroderma, Localized / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D012595:Scleroderma, Systemic / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D012867:Skin / Q000000981:diagnostic imaging* / Q000473:pathology; D013817:Thermography; D041623:Tomography, Optical Coherence; D018608:Ultrasonography, Doppler; D014605:Uveitis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid; C502936:tocilizumab; D008727:Methotrexate
keywords: Biomarkers; Doppler ultrasonography; Juvenile localized scleroderma; Juvenile systemic sclerosis